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Elevated markers of neuroinﬂammation have been found to be associated with many
psychiatric and neurodegenerative diseases, such as mood disorders, Alzheimer’s dis-
ease, and multiple sclerosis (MS). Since neuroinﬂammation is thought to contribute to the
pathophysiology of these diseases and to impair responses to therapeutic interventions
and recovery, it is important to identify mechanisms that regulate neuroinﬂammation and
potential targets for controlling neuroinﬂammation. Recent ﬁndings have demonstrated
that glycogen synthase kinase-3 (GSK3) is an important regulator of both the innate and
adaptive immune systems’ contributions to inﬂammation. Studies of the innate immune
system have shown that inhibitors of GSK3 profoundly alter the repertoire of cytokines that
are produced both by peripheral and central cells, reducing pro-inﬂammatory cytokines,
and increasing anti-inﬂammatory cytokines. Furthermore, inhibitors of GSK3 promote tol-
erance to inﬂammatory stimuli, reducing inﬂammatory cytokine production upon repeated
exposure. Studies of the adaptive immune system have shown that GSK3 regulates the
production of cytokines byT cells and the differentiation ofT cells to subtypes, particularly
Th17 cells. Regulation of transcription factors by GSK3 appears to play a prominent role in its
regulation of immune responses, including of NF-κB, cyclic AMP response element binding
protein, and signal transducer and activator of transcription-3. In vivo studies have shown
that GSK3 inhibitors ameliorate clinical symptoms of both peripheral and central inﬂamma-
tory diseases, particularly experimental autoimmune encephalomyelitis, the animal model
of MS. Therefore, the development and application of GSK3 inhibitors may provide a new
therapeutic strategy to reduce neuroinﬂammation associated with many central nervous
system diseases.
Keywords: glycogen synthase kinase-3, GSK3, inflammation, cytokines, EAE, multiple sclerosis, mood disorders,
neurodegenerative diseases
INTRODUCTION
The immune system responds to infection or damage to attempt
to restore homeostasis. Immune system responses are classiﬁed
as adaptive or innate based on the activation timing and antigen
presentation. Innate immune cells provide the ﬁrst line of defense
against pathogens, acting as sentinels to detect signs of distress.
Upon the ﬁrst signs of distress, activated sentinel cells of the innate
immune system release soluble mediators of inﬂammation, such
as cytokines and chemokines, to clear the pathogen. On the other
hand, adaptive immunity is a slower response dependent on T cells
and B cells reacting with antigen-presenting cells. Together, the
innate and adaptive immune systems contribute to the process of
inﬂammation, and dysregulation of either system can contribute
to a variety of pathological conditions. Importantly, immune cell
activation is usually rapidly reversed by anti-inﬂammatory and
immunosuppressive functions in order to avoid damaging the
host. Although the immune responses are mainly thought to be
triggered in the periphery, there are also organ specialized immune
cells, which exhibit unique immune function.
There is growing recognition that inﬂammatory signaling mol-
ecules have profound inﬂuences on many functions of the central
nervous system (CNS). These effects include actions of both the
innate and adaptive immune systems, as well as glia within the
CNS (Raison et al., 2006; Dantzer et al., 2008; Miller et al., 2009;
Miller, 2010). While it is important to remember that many of
these neuroimmune actions are beneﬁcial, as well as necessary,
for a healthy CNS, research has been particularly focused on
detrimental effects of neuroinﬂammation in association with psy-
chiatric and neurodegenerative diseases. This has raised awareness
that much remains to be learned about signaling mechanisms
that regulate neuroinﬂammation, and that targeting regulators of
neuroinﬂammation may prove to be a useful therapeutic strat-
egy capable of affecting a diverse array of CNS disorders. Recent
evidence is reviewed here demonstrating that glycogen synthase
kinase-3 (GSK3) is an important regulator of both innate and
adaptive immune system mediators that can profoundly affect the
CNS.
NEUROINFLAMMATION
In contrast to other organs, the brain does not display a classical
immune response but is capable of mounting its own inﬂam-
matory responses. The blood brain barrier serves to separate the
brain’s local inﬂammatory responses from systemic inﬂamma-
tion by limiting, but not entirely preventing, the penetration of
Frontiers in Molecular Neuroscience www.frontiersin.org August 2011 | Volume 4 | Article 18 | 1
Beurel GSK3 promotes neuroinﬂammation
peripheral inﬂammatory mediators and immune cells (Lampson,
1987; Fuchs and Bullard, 1988). This unique protection from sys-
temic inﬂammation likely developed to protect neurons, since
they are long-lived cells with limited capacity to recover from
noxious insults. However, although for many years the immune
privileged status of the CNS was misinterpreted to mean exclu-
sion of immune cells, it is now evident that “immunosurveil-
lance is an integral part of the functioning brain” (Schwartz and
Shechter, 2010). In the CNS, microglia are the sentinel cells that
constantly survey the environment and become activated to pro-
duce an inﬂammatory response to infection or damage (Kim and
De Vellis, 2005). In conjunction with microglia responses, astro-
cytes are also well-established to contribute to neuroinﬂammatory
responses (Lieberman et al., 1989; Hamby and Sofroniew, 2010).
Acutely or chronically, these glial responses could be beneﬁcial or
detrimental because they allow microglia to migrate to afﬂicted
sites where they produce cytokines and growth factors that can
contribute to the recovery, or be deleterious, for affected neu-
rons, and may contribute to many diseases of the nervous system
(Matyszak, 1998; Correale andVilla, 2004; Campbell, 2005; Cartier
et al., 2005; Hauwel et al., 2005; Kim and De Vellis, 2005; Imitola
et al., 2006; Kielian, 2006; Schwartz et al., 2006). Thus, it is crucial
to identify mechanisms that induce and regulate neuroinﬂamma-
tion. The prevalence of markers of inﬂammation associated with
psychiatric and neurodegenerative diseases suggest there is pro-
longed activation and impaired down-regulation of neuroinﬂam-
mation in these conditions, including inﬂuences by the peripheral
immune system. Thus, it remains difﬁcult to dissociate distinct
contributions of the peripheral and CNS inﬂammatory systems,
making it challenging to identify therapeutic targets to control
neuroinﬂammation.
GSK3 PROMOTES NEUROINFLAMMATION
Inﬂammatory responses were ﬁrst found to be promoted by GSK3
following stimulation of several types of toll-like receptors (TLR)
in monocytes and peripheral blood mononuclear cells (Mar-
tin et al., 2005). This demonstrated that GSK3 is necessary for
full stimulation of the production of several pro-inﬂammatory
cytokines, such as interleukin-6 (IL-6), IL-1β, and tumor necro-
sis factor-α (TNFα), and inhibitors of GSK3 greatly reduced
the production of pro-inﬂammatory cytokines. Remarkably, in
vivo administration of GSK3 inhibitors provided protection from
endotoxin shock sufﬁciently enough to allow the survival of most
mice from an otherwise lethal (LD100) dose of lipopolysaccha-
ride (LPS; Martin et al., 2005). This study showed for the ﬁrst
time the powerful ability of GSK3 inhibitors to shift the balance
of the inﬂammatory response from pro-inﬂammatory to anti-
inﬂammatory, and revealed the therapeutic potential for these
drugs in inﬂammatory conditions (Martin et al., 2005). These
ﬁndings raised the novel possibility that inhibitors of GSK3 may
prove to be beneﬁcial in conditions involving inﬂammation (Jope
et al., 2007).
The pro-inﬂammatory action of GSK3 and anti-inﬂammatory
actions of its inhibitors have been demonstrated with a variety of
inﬂammatory molecules and extended to several cell types (Gao
et al., 2008; Wang et al., 2009a,b, 2011a; Gurrieri et al., 2010;
Kao et al., 2010; Klamer et al., 2010; Baarsma et al., 2011; for
review Beurel et al., 2010), including cells in the CNS that con-
tribute to neuroinﬂammation. In LPS-stimulatedmicroglia,GSK3
promotes the production of cytokines and other inﬂammatory
molecules, such as IL-1β, TNFα, IL-6, IL-8, RANTES, CXCL-10,
and nitric oxide (NO; Luna-Medina et al., 2005; Hashioka et al.,
2007;Beurel and Jope,2009b;Cheng et al., 2009;Huang et al., 2009;
Yuskaitis and Jope, 2009). As in the periphery, NF-κB is thought
to be a critical transcription factor targeted by GSK3 for pro-
moting neuroinﬂammation (Yuskaitis and Jope, 2009;Wang et al.,
2010), as discussed below. In addition tomicroglia,GSK3 also pro-
motes cytokine production by astrocytes (Park et al., 2006; Beurel
and Jope, 2010), in particular IL-6, and promotes the IL-6/signal
transducer and activator of transcription-3 (STAT3)-dependent
activation of glial ﬁbrillary acidic protein (GFAP), which is a criti-
calmarker of astrogliosis (Beurel and Jope,2008,2009b). Tolerance
is a mechanism whereby cells dampen their response to two con-
secutive identical stimuli, and the promotion of IL-6 production
by GSK3 was shown to also involve GSK3 counteracting LPS-
induced tolerance for IL-6 production in astrocytes (Beurel and
Jope, 2010).
Besides regulating cytokine production in glia, GSK3 also pro-
motes migration and activation of glial cells (Beurel and Jope,
2008; Yuskaitis and Jope, 2009). Inhibition of GSK3 promotes
microglial survival during oxygen–glucose deprivation (Chong
et al., 2007) and treatment with erythropoietin both inhib-
ited GSK3 and supported microglia survival (Li et al., 2006),
actions that may contribute to minimizing permanent CNS
damage.
Recently, inhibition of GSK3 was suggested to promote stabi-
lization of the brain blood barrier (Ramirez et al., 2010). This
was based on ﬁndings in cultured brain microvascular endothe-
lial cells that GSK3 inhibition reduced the production of several
inﬂammatorymolecules andmonocyte adhesion to andmigration
across cytokine-stimulated cells. Furthermore, in vivo inhibition
of GSK3 reduced leukocyte adhesion to brain endothelium under
inﬂammatory conditions.
PRO-INFLAMMATORY MECHANISMS OF GSK3
GSK3 CAN PROMOTE PRO-INFLAMMATORY CYTOKINE PRODUCTION
THROUGH NF-κB ACTIVATION
Regulation of the inﬂammatory transcription factor NF-κB was
found to be key for the pro-inﬂammatory actions of GSK3 (Mar-
tin et al., 2005; Gong et al., 2008a,b; Yuskaitis and Jope, 2009;
Wang et al., 2010). Inhibitors of GSK3 reduced TLR-induced
production of inﬂammatory cytokines by inhibiting the transcrip-
tional activation of NF-κB (Martin et al., 2005). This supported
previous reports that GSK3 is necessary for the full transcrip-
tional activity of NF-κB (Hoeﬂich et al., 2000), and that GSK3
supported NF-κB transcriptional activity in a promoter-speciﬁc
manner (Steinbrecher et al., 2005). This selective action of GSK3β
on NF-κB-induced inﬂammatory gene expression may facilitate
the therapeutic anti-inﬂammatory uses of GSK3 inhibitors since
it indicates that inhibition of GSK3 will not interfere with all the
actions of NF-κB. The role of GSK3 in the regulation of NF-κB
in inﬂammation was further expanded by the demonstration of a
role for GSK3 in the desensitization of LPS-induced inﬂammatory
signaling by TNFα (Park et al., 2011).
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GSK3 BLOCKS ANTI-INFLAMMATORY CYTOKINES
Conversely to inﬂammatory signaling, GSK3 reduces the produc-
tion of the anti-inﬂammatory cytokine IL-10, and inhibitors of
GSK3 increased anti-inﬂammatory cytokine production (Martin
et al., 2005; Hu et al., 2006; Antoniv and Ivashkiv, 2011; Ren et al.,
2011). Inhibition of IL-10 production by GSK3 was reported to
involve a competition for limiting amounts of CBP/p300, with
GSK3-promoted activation of NF-κB depleting the amount of
CBP/p300 available for cyclic AMP response element binding pro-
tein (CREB)-induced IL-10 production (Martin et al., 2005; Hu
et al., 2006; Hofmann et al., 2010). It was also proposed that
the down-regulation of IL-10 production by GSK3 contributes to
the synergistic inﬂammatory signaling induced by co-treatment
with interferons and TLR ligands (Hu et al., 2006; Lin et al.,
2008). Furthermore, the production of IL-10 by IFNβ, thought
to be important for the anti-inﬂammatory therapeutic proper-
ties of IFNβ in multiple sclerosis (MS) patients, was shown to be
dependent on inhibition of GSK3 (Wang et al., 2011a).
TGFβ1 also has anti-inﬂammatory properties. Although the
mechanism whereby TGFβ1 suppresses inﬂammation remains
unclear, it has been proposed that TGFβ1 can antagonize the
production of certain pro-inﬂammatory cytokines in response to
inﬂammatory stimuli by inhibition of GSK3 to promote β-catenin
signaling (Dai et al., 2011). Additionally, it is also thought that
because TGFβ is required for the induction of regulatory T cells
(Tregs), which produce IL-10, the anti-inﬂammatory action of
TGFβ is mediated through its induction of Tregs in vivo where
Tregs counteract the action of the pro-inﬂammatory effector
CD4+ T cells and of the pro-inﬂammatory cytokines (Campbell
and Koch, 2011). Recently, it was shown that inhibition of GSK3
increases the anti-inﬂammatory properties of Tregs by increasing
β-catenin levels in response to TGFβ (Graham et al., 2010). GSK3
was also shown to regulate activation of Smad transcription fac-
tors (Fuentealba et al., 2007; Sapkota et al., 2007; Guo et al., 2008;
Liang et al., 2008; Heldin et al., 2009), indicating a direct effect of
GSK3 on the TGFβ-induced signaling pathway.
Therefore, it appears that NF-κB activation is a key pro-
inﬂammatory pathway promoted by GSK3, whereas CREB and
β-catenin are inhibited by GSK3 to maintain low levels of
anti-inﬂammatory molecules.
COOPERATION OF GSK3 WITH mTOR TO REGULATE CYTOKINE
PRODUCTION
A number of inﬂammatory signaling pathways converge on GSK3
to regulate cytokine production, reinforcing the concept thatGSK3
has a central role in the regulation of cytokine production and
other inﬂammatory outcomes. GSK3 promotes the activation of
myeloid dendritic cells (DC) and their secretion of cytokines (Ono
et al., 2007; Rodionova et al., 2007; Hoarau et al., 2008; Larabee
et al., 2011; Liu et al., 2011;Wang et al., 2011b). During DC gener-
ation, inhibition of the mammalian target of rapamycin (mTOR)
confers resistance to maturation, whereas inhibition of mTOR
prior to TLR activation enhanced pro-inﬂammatory cytokine pro-
duction. GSK3 activity was shown to be inhibited by the mTOR
pathway and modulated the capacity of DCs to produce pro-
inﬂammatory cytokines (Turnquist et al., 2010; Brown et al., 2011;
Wang et al., 2011b). The production of cytokines by DCs also
inﬂuences the differentiation of T helper (Th) cells (Ono et al.,
2007) that are highly dependent on cytokines to differentiate
toward different lineages (O’Shea and Paul, 2010).
GSK3 INFLUENCES IMMUNE CELL FATE
Glycogen synthase kinase-3 also regulates other transcription fac-
tors involved in inﬂammation besides NF-κB and CREB, particu-
larly STATs. This allows GSK3 to control the amplitude and the
duration of inﬂammatory responses. Thus, it was shown that
GSK3 participates in the synergistic action of IFNγ on LPS-
induced signaling in part bymodulating the downstream signaling
induced by IFNγ, the JAK/STAT pathway. Although GSK3 was
not involved in the short term activation of IFNγ-induced STAT1
(Beurel and Jope,2008), inhibitors of GSK3blocked IFNγ-induced
STAT1 activation at longer times in macrophages through SHP2
derepression (Tsai et al., 2009). Furthermore, a differential role
of GSK3 in regulating the activation of different STAT subtypes
was uncovered, as GSK3 was found to promote STAT3 and STAT5
activation, while GSK3 did not affect STAT6 activation (Beurel
and Jope, 2008). This regulation of STAT3 activation by GSK3
may be particularly relevant for the signaling induced by IL-6, as
well as for the production of IL-6 in response to both LPS and the
combination LPS and IFNγ (Beurel and Jope, 2009a,b).
Although GSK3 has been mainly thought of as a regulator of
cytokine production, an unexpected role of GSK3 was found to
be in the regulation of the differentiation of Th subsets. Cytokines
are key determinants for Th differentiation toward a particular
lineage and STAT3 is a crucial instigator of the differentiation
toward Th17 cells (O’Shea and Paul, 2010). Thus, it was found
that GSK3 is required for Th17 cell production, perhaps due to
both promoting IL-6 production and STAT3 activation (Harring-
ton et al., 2005), although other processes likely also contribute to
this action of GSK3 on Th17 cells (Beurel et al., 2011). This recent
discovery that GSK3 promotes Th17 cell differentiation provides
a new step in the understanding of the GSK3-dependent regula-
tory mechanisms of the immune system. Th17 cells are critical for
the pathogenicity of many autoimmune diseases (Langrish et al.,
2005; Ivanov et al., 2006; Komiyama et al., 2006), so the ﬁnding
that inhibition of GSK3 blocked Th17 cell differentiation provides
a new avenue of therapeutic intervention that may contribute to
controlling Th17-driven diseases.
SURVIVAL ADVANTAGES OF BLOCKING GSK3 ACTIVITY
Glycogen synthase kinase-3 has long been known to promote cell
death mediated by the intrinsic apoptotic pathway, whereas it pro-
tects from extrinsic apoptosis (Beurel and Jope, 2006; Sun et al.,
2008). Several apoptosis-regulating properties of GSK3 have been
identiﬁed in the immune system. Thus, for example, during the
clonal expansion of activated T cells, there is induction of the acti-
vated T cell death (ACTD; Kondrack et al., 2003), which is thought
to be due to a loss of access to survival signals. ACTD is thought
to be critical to prevent autoimmune responses, but need to be
tightly regulated because complete elimination of responding T
cells would confer increased susceptibility to infections. GSK3 was
shown to be required for ACTD and inhibition of GSK3 promotes
survival of T cells (Sengupta et al., 2007). GSK3 was also found to
be critical to induce apoptosis of DC (Hoarau et al., 2008).
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Altogether, GSK3 promotes pro-inﬂammatory cytokine pro-
ductionby regulating anetworkof transcription factors.GSK3also
receives signals in order to ﬁnely tune this cytokine production.
But GSK3 also, intrinsically to immune cells, affects their matu-
ration, differentiation, and survival rendering GSK3 an attractive
target for therapeutic interventions.
INFLAMMATION IN PSYCHIATRIC DISEASES
The mood disorders depression and bipolar disorder are preva-
lent diseases with a high lifetime incidence of ∼20% in the US
(Greden, 2001; Belmaker and Agam, 2008), but current treat-
ments are often inadequate, as many patients do not respond or
prematurely terminate treatment (Krishnan and Nestler, 2008).
Much evidence has shown thatmood disorders are associated with
alterations of the immune system, especially increased markers
of inﬂammation. For example, extensive evidence has demon-
strated that inﬂammation promotes susceptibility to depression
and impairs responses to antidepressants. Elevated serum levels
of inﬂammatory cytokines, such as the cytokines IL-6 and TNFα,
have been reported in patients with major depression or bipo-
lar disorder (Anisman and Merali, 2003; O’Brien et al., 2004a,
2006, 2007; Schiepers et al., 2005; Raison et al., 2006; Dantzer
et al., 2008; Miller et al., 2009; Miller, 2010). A signiﬁcant portion
of people develop depression following the therapeutic bolster-
ing of immunity by interferon-α administration (Reichenberg
et al., 2001; Wright et al., 2005; Prather et al., 2009). Depres-
sive symptoms thought to be due to cytokines also occur after
a mild activation of the innate immune system (Raison et al.,
2006; Dantzer et al., 2008; Miller et al., 2009). Antidepressants are
less effective in patients with activated inﬂammation, and antide-
pressant responses are improved in some patients by co-treatment
with anti-inﬂammatory drugs (O’Brien et al., 2007; Roumestan
et al., 2007; Dantzer et al., 2008; Miller et al., 2009; Rivest, 2009).
Administration of drugs that inhibit the actions of cytokines or
their signaling pathways, such as cyclooxygenase inhibitors and
etanercept, improve mood in patients with inﬂammatory diseases
(Mendlewicz et al., 2006; Muller et al., 2006; Tyring et al., 2006).
These links demonstrating inﬂammation increases susceptibil-
ity to mood disorders have been recapitulated in rodents. For
example, administration of individual inﬂammatory cytokines,
or of LPS to induce inﬂammation, causes depression-like behav-
iors in rodents that are reversed by antidepressant administration
(Dantzer and Kelley, 2007). Increased cytokine levels or admin-
istration of cytokines in rodents or humans have been reported
to induce behavioral changes with characteristics similar to mood
disorders (Licinio and Wong, 1999; Hayley et al., 2005; Simen
et al., 2006). Importantly, psychological stress in both humans and
rodents is sufﬁcient to activate the production of inﬂammatory
cytokines and to induce depressive symptoms (Anisman and Mer-
ali, 2003; O’Brien et al., 2006; Gabbay et al., 2009). Thus, there is
much evidence that inﬂammation can precipitate depression and
impair therapeutic responses. While it remains to be determined
if inﬂammatory cytokines contribute to the onset or represent an
outcome of mood disorders, it has been suggested that reduc-
ing inﬂammation may contribute to therapeutic interventions
based on the depressive effects that cytokines can produce and
on evidence that classical antidepressants are anti-inﬂammatory
(Reynolds et al., 2005; Schiepers et al., 2005).
While many investigators have focused on actions of the innate
immune system in depression, the impact of the adaptive immune
system, especially T cells, remains poorly understood even though
the innate and adaptive immune systems are highly integrated.
Examinations of the effects of stress and depression on T cell
responses demonstrated altered proliferation of peripheral blood
mononuclear cells in response to stimulation with T cell mito-
gens in samples from patients with depression (Bartrop et al.,
1977; Kronfol et al., 1983; Schleifer et al., 1983, 1984; Stein et al.,
1991). T cell alterations also were indicated by in vivo measure-
ments of T cell-mediated immune function in depressed patients
(Hickie et al., 1993; Sephton et al., 2009). Studies of mechanisms
implicated increased Fas-mediated T cell apoptosis (Eilat et al.,
1999; Ivanova et al., 2007; Szuster-Ciesielska et al., 2008), reduced
T cell responses to glucocorticoids that are elevated in major
depression (Pariante and Miller, 2001), or increased cytokine lev-
els that modulate T cell subtype production and responses (Cope
et al., 1994, 1997; Lee et al., 2008). These and additional reports
(Miller, 2010) of altered T cells in depression led to demonstra-
tions that T cells mediate the negative impact of depression on
health outcomes in depressed patients with infectious diseases or
cancer.
Substantial evidence indicates that dysregulated GSK3 con-
tributes to mood disorders (Li and Jope, 2010): brain GSK3 is
abnormally active in postmortem human prefrontal cortex from
depressed subjects (Karege et al., 2007),GSK3 is activated inmouse
brain in the learned helplessness model of depression (Polter et al.,
2010), antidepressants inhibit GSK3 (Li et al., 2004), reducing
GSK3 activity ameliorates depression-like behaviors in rodents
(Gould et al., 2003; Kaidanovich-Beilin et al., 2004; O’Brien et al.,
2004b; Beaulieu et al., 2008), and abnormally active GSK3 inGSK3
knockin mice increases susceptibility to depression-like behav-
iors (Polter et al., 2010). Since inﬂammation is a candidate cause
of increased susceptibility to depression, it is notable that GSK3
strongly promotes inﬂammation in the periphery (Martin et al.,
2005) and CNS (Beurel and Jope, 2009b, 2010; Yuskaitis and Jope,
2009), which is reduced by GSK3 inhibitors. GSK3 knockin mice
showed also a mild exacerbation of their depressive-like behavior
in response to LPS administration compared to wild-type mice
(Polter et al., 2010). Therefore, part of the therapeutic effects
of the mood stabilizer lithium, as well as of antidepressants that
inhibit GSK3, may come from their anti-inﬂammatory effects fol-
lowing inhibition of GSK3. However, further investigations are
needed to deﬁnitively test if promotion of inﬂammation by GSK3
contributes to mood disorders.
INFLAMMATION IN NEURODEGENERATIVE DISEASES
Inﬂammatory markers, particularly increased levels of inﬂamma-
tory cytokines and activated microglia and astrocytes, have been
reported in many neurodegenerative diseases, such as Alzheimer’s
disease (AD), Parkinson’s disease (PD), and amyotrophic lat-
eral sclerosis, as well as MS, which is generally considered an
autoimmune disease (Amor et al., 2010; Glass et al., 2010; Philips
and Robberecht, 2011). This may be due to impaired mecha-
nisms of inﬂammation resolution or persistent stimulation of
inﬂammatory responses, such as may be caused by the genera-
tion of “danger” signals from degenerating neurons that activate
damage-associatedmolecular patterns (DAMPs).Activation of the
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inﬂammatory systemhas beneﬁcial effects, such as phagocytosis of
dead cells and production of factors bolstering neuronal function
and neurogenesis. However, it is generally thought that long-term
inﬂammation associated with neurodegenerative diseases exacer-
bates the diseases by releasing signalingmolecules that impair neu-
ronal function and survival, increasing the impairments associated
with the primary disease lesion.
ALZHEIMER’S DISEASE
Alzheimer’s disease is a severe, progressive neurodegenerative
disease with a growing prevalence and only modestly effective
therapies are available. There are two classical neuropathological
features of AD: intraneuronal ﬁlamentous aggregates of hyper-
phosphorylated tau and other proteins called neuroﬁbrillary tan-
gles, and extracellular deposits of aggregated amyloid-β (Aβ)
peptides called amyloid plaques. The levels of many cytokines,
such as IL-1β, IL-6, and TNFα, and chemokines are upregulated
in AD, as previously reviewed (Akiyama et al., 2000; Block and
Hong, 2005; Sastre et al., 2006). This inﬂammation and increased
cytokine production is also exhibited by transgenic mouse models
of AD (Benzing et al., 1999; Matsuoka et al., 2001). Activation of
astrocytes andmicroglia and the ensuing production of inﬂamma-
tory molecules has been reported to be stimulated by degenerating
neurons, neuroﬁbrillary tangles, and Aβ and other cleavage prod-
ucts of amyloid precursor protein, and activated astrocytes and
microglia are found surrounding amyloid plaques in AD brain
(Bach et al., 2001; Combs et al., 2001; Ho et al., 2005). Inﬂam-
mation may contribute to the increased risk for AD following
traumatic brain injury or diabetes, both of which can cause
increased inﬂammation, as well as to the prevalent co-morbidity
of depression with AD, since much evidence links inﬂammation
with depression as discussed above. Many investigations have
reported evidence that hyperactive GSK3 in AD contributes to
both of its neuropathological hallmarks by phosphorylating tau
and promoting Aβ production (Jope and Johnson, 2004; Lesort
and Jope, 2010) and to neuronal death (Beurel and Jope, 2006;
Mines et al., 2011). These many links between AD and GSK3 have
led to a substantial effort to develop GSK3 inhibitors for treating
AD (Hooper et al., 2008;Martinez and Perez, 2008;Muyllaert et al.,
2008; Hernandez et al., 2010). GSK3 inhibitors reduce inﬂamma-
tory mediators implicated in AD, such as NO (Yuskaitis and Jope,
2009) and inﬂammatory cytokines (Beurel et al., 2010). Consider-
ing the evidence for inﬂammation contributing to AD pathology
and that GSK3 promotes inﬂammation, interventions with GSK3
inhibitors may also be beneﬁcial by reducing the inﬂammation
that is thought to exacerbate neurodegenerative processes in AD.
PARKINSON’S DISEASE
Like many other neurodegenerative diseases, substantial evidence
indicates that neuroinﬂammation contributes to PD, and its mod-
els in rodents. For example, activated inﬂammatory processes in
the substantia nigra have been implicated in the loss of dopamin-
ergic neurons in PDpatients and in animalmodels of PD (Esposito
et al., 2007; Hald et al., 2007; Mcgeer and Mcgeer, 2008; Bar-
num and Tansey, 2010), and some (Gagne and Power, 2010),
but not all (Wahner et al., 2007; Driver et al., 2011), stud-
ies have indicated that non-steroidal anti-inﬂammatory drug
use reduces the risk of PD. However, the innate immune sys-
tem may not be acting alone in promoting PD. Evidence has
been reported of activated T cells in the substantia nigra in
rodent PD models (Kurkowska-Jastrzebska et al., 1999) and post-
mortem PD brains (Brochard et al., 2009), and elimination of T
cells attenuated dopaminergic neuron loss in rodent PD mod-
els (Brochard et al., 2009). As in AD, there is evidence both
that GSK3 contributes to neuronal degenerative processes in PD
(King et al., 2001; Chen et al., 2004) and that neurotoxic mech-
anisms, such as α-synuclein in PD, activate GSK3 (Duka et al.,
2009; Yuan et al., 2010). Thus, inhibition of GSK3 may protect
susceptible neurons from degeneration and reduce the inﬂam-
mation that appears to promote neurodegenerative processes
in PD.
MULTIPLE SCLEROSIS
Multiple sclerosis appears to result from aberrant innate and adap-
tive immune system actions in the CNS, likely initiated by an
autoimmune response that causes inﬂammation, demyelination,
and neuronal degeneration (Weiner, 2008). Thus, in contrast to
the other neurodegenerative diseases that appear to initiate with
neuronal insults,MS is initiated by aberrant actions of the adaptive
immune system. Studies of MS patients and of the animal model
of MS (experimental autoimmune encephalomyelitis, EAE) have
implicated the Th17 and Th1 subsets of Th cells as key mediators
of the disease (Langrish et al., 2005; Ivanov et al., 2006; Tzartos
et al., 2008). This ﬁrst wave of adaptive immune system activ-
ity and inﬂammation seems to be followed by a second wave of
neuroinﬂammation, and both are thought to contribute to the
death of oligodendrocytes. Thus, inﬂammation with activation of
microglia and astrocytes are well-established components of MS
and targeting the response of these cells has been explored (Kang
et al., 2010).
The crucial inﬂammatory component of MS suggests that
inhibitors of GSK3 may provide some amelioration of the dis-
ease. Indeed, in EAE, administration of lithium to inhibit GSK3
effectively prevents the disease and almost completely terminates
ongoing disease (De Sarno et al., 2008; Beurel et al., 2011). Notably,
inhibitors of GSK3 also prevent production of Th17 cells that
are critical for the disease (Beurel et al., 2011), suggesting that
GSK3 inhibitors provide at least two actions that may contribute
to alleviation of MS.
CONCLUSION
Glycogen synthase kinase-3 is now well-established to contribute
to inﬂammatory processes in the periphery, and growing evi-
dence indicates thatGSK3 also promotes neuroinﬂammation. This
action appears to be largely the result of GSK3promoting the activ-
ities of transcription factors that mediate inﬂammatory responses,
particularly NF-κB and STAT3. Furthermore, although both par-
alogs of GSK3, GSK3α and GSK3β, share many common actions,
there is increasing evidence that they can also have non-redundant
functions (Hoeﬂich et al., 2000; Liang andChuang,2006; Force and
Woodgett, 2009). Most of the studies on inﬂammation focused
on GSK3β, mainly because more tools have been developed for
studying GSK3β. However, there is a differential role of GSK3α
and GSK3β in the regulation of IL-6 production (Beurel and
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Jope, 2008). Therefore, identifying differential role for GSK3α and
GSK3βmay be a promising avenue for future studies. Importantly,
GSK3 has been implicated in pathological processes of psychi-
atric and neurodegenerative diseases that also exhibit increased
inﬂammatory activation, such as mood disorders, AD, PD, and
MS. Thus, GSK3 may provide a feasible therapeutic target to
control inﬂammation along with ameliorating other pathological
processes in several diseases of the CNS.
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